Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma

International Journal of Cancer

Volumn 111, Issue 4, 2004, Pages 627-632

  Albrecht, Steffen ^a   Hartmann, Wolfgang ^b   Houshdaran, Farzad ^b   Koch, Arend ^b   Gärtner, Barbara ^c   Prawitt, Dirk ^c   Zabel, Bernhard U ^c   Russo, Pierre ^d   Von Schweinitz, Dietrich ^e   Pietsch, Torsten ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chromosome region 11p15.5; Embryonal tumors; Tumor suppressor genes

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA;

ALLELE; ARTICLE; BWR1A GENE; CHILD; CHROMOSOME 11P15.5; CHROMOSOME LOSS; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE; GENE EXPRESSION; GENE LOCATION; GENE LOSS; GENE MUTATION; GENETIC SCREENING; GENOME IMPRINTING; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LIVER CARCINOGENESIS; LIVER DEVELOPMENT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TELOMERE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION PROFILING; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; ORGANIC CATION TRANSPORT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3843134318     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20280     Document Type: Article

References (34)

1. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999;59:269-73.
2. Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas: a role for Gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000;157:571-8.
3. Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau M, Cavenee W. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991;58:1080-96.
4. Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A, Hatada I, Mukai T, Ohashi H, Barbanti-Brodano G, Croce CM, Negrini M. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA 1998;95:3873-8.
5. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1 derived from human hepatoblastoma. Lab Invest 1995;74:809-18.
6. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976;67:1-10.
7. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-6.
8. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983;14:512-37.
9. Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994;54:5041-4.
10. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavanee WK, Wiestler OD. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropthol 1997;93:109-17.
11. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem 1984;32:219-29.
12. Bepler G, Garcia-Blanco MA. Three tumor suppressor regions on chromosomes 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci USA 1994;91:5513-7.
13. Winqvist R, Mannermaa A, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W. Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res 1993;53:4486-8.
14. Pitterle DM, O'Briant KC, Kim YC, Schreiber G, Bepler G. Physical map and genes in the LOH11A metastasis suppressor region on chromosome 11. Proc Am Assoc Cancer Res 1999;40:544.
15. Falls JG, Pulford DJ, Wylie AA, Jirtle RL. Genomic imprinting: implications for human disease. Am J Pathol 1999;154:635-47.
16. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. Disruption of imprinting caused by deletion of the H19 region in mice. Nature 1995;375:34-9.
17. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA. Nature 1993;365:764-7.
18. Ariel I, Sappir M, Lustig O, De-Groot N, Schneider T, Hochberg A. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995;45:335-8.
19. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995;10:1193-8.
20. CIP2 inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-62.
21. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
22. KIP2 mutations in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997;61:304-9.
23. KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms' tumors. Am J Hum Genet 1997;61:295-303.
24. KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 1996;14:171-3.
25. KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 1996;5:783-8.
26. Chung WY, Yuan L, Feng L, Hensle T, Tycko B. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. Hum Mol Genet 1996;8:1101-8.
27. KIP2 defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour. Oncogene 1997;14:1201-6.
28. KIP2 is expressed in Wilms' tumor with LOH of 11p15.5. Genes Chromosomes Cancer 1996;17:56-9.
29. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, Pietsch T. p57 (KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57 (KIP2), IGF2, and H19. Am J Pathol 2000;157:1393-403.
30. KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Res 1996;56:1219-21.
31. KIP2 gene at 11p15.5. Oncogene 1996;12:1365-8.
32. Lee MP, Reeves C, Schmitt A, Su K, Connors TD, Hu RJ, Brandenburg S, Lee MJ, Miller G, Feinberg AP. Somatic muation of TSSC5, a novel imprinted gene from human chromosome 11p15.5. Cancer Res 1998;58:4155-9.
33. Dao D, Frank D, Qian N, O'Keefe D, Vosatka RJ, Walsh CP, Tycko B. IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet 1998;7:597-608.
34. Cooper PR, Smilinich NJ, Day CD, Nowak NJ, Reid LH, Pearsall RS, Reece M, Prawitt D, Landers J, Housman DE, Winterpacht A, Zabel BU, et al. Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain. Genomics 1998;49:38-51.